Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2115 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Single dose of AZD2115 25 µg | EXPERIMENTAL | - |
| Single dose of AZD2115 80 µg | EXPERIMENTAL | - |
| Single dose of AZD2115 240 µg | EXPERIMENTAL | - |
| Single doses of placebo | PLACEBO_COMPARATOR | - |
| Single dose of indacaterol 150 µg | ACTIVE_COMPARATOR | - |
| Single dose of indacaterol 150 µg + tiotropium 18 µg | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | AZD2115 |
| 2 | PLACEBO_COMPARATOR | Placebo to AZD2115 |
| Name | Type | Description |
|---|---|---|
| AZD2115 | DRUG | AZD2115 administered via inhalation |
| Placebo | DRUG | Placebo administered via inhalation |
| Indacaterol | DRUG | Indacaterol administered via inhalation |
| Indacaterol + Tiotropium | DRUG | Indacaterol + Tiotropium administered inhalation |
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * Male or female of non-childbearing potential (post-menopausal or surgically sterilised), age ≥40 years at Visit 1 * Clinical diagnosis of COPD for more than 1 year at Visit 1, according to GOLD guidelines *...
Top 11 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 8 | PHASE3 | Depemokimab, GSK5784283, GSK3862995B |
| AstraZeneca PLC | AZN | 14 | PHASE3 | Tezepelumab, Breztri, Bevespi, Tozorakimab, AZD6793 |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Lunsekimig, SAR447537, Dupilumab |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Ensifentrine, Frespaciguat |
| Pfizer Inc. | PFE | 2 | PHASE3 | Tilrekimig, PF-07275315 |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Alpha-1 MP |
| Hoffmann-La Roche | RHHBY | 4 | PHASE3 | Astegolimab, RO7830698, GDC-6988 |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Generate Biomedicines, Inc. | GENB | 1 | PHASE1 | GB-0895 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | Tyvaso (treprostinil) |
AZD2115 is an investigational inhaled small molecule being studied for the treatment of chronic obstructive pulmonary disease (COPD). It is not approved for any indication and remains in clinical development, with studies conducted in COPD patients and in healthy volunteers.
AZD2115 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. The company sponsored the clinical studies of the drug in COPD and in healthy volunteers.
AZD2115 has reached Phase 2 clinical development. A Phase 2 study of inhaled AZD2115 in COPD patients has been completed, and a Phase 1 single ascending dose study has also been completed. The drug is investigational and has not been approved by the FDA.
AZD2115 has been evaluated in two completed trials. NCT01498081 was a Phase 2, randomized, double-blind, placebo-controlled single-dose study of three inhaled dose levels in 39 COPD patients in Poland and Sweden. NCT01283984 was a Phase 1 single ascending dose study in 96 healthy male volunteers in the United Kingdom.
The Phase 2 trial, NCT01498081, was a single-dose study investigating three different doses of inhaled AZD2115 in COPD patients. It was randomized, double-blind, and placebo-controlled, enrolled 39 participants aged 40 years and older, and was conducted in Poland and Sweden. The study has been completed.